Emmaus Life Sciences EMMA
OTC EMMA
$0.06 +0.00 (+0.00%)
At close: Oct 21, 2026 · 4:00 PM EDT

Emmaus Life Sciences (EMMA) Gains from Sales and Divestitures (2021)

Updated

Emmaus Life Sciences (EMMA) recorded Gains from Sales and Divestitures of -$1,000 in FY2023, compared with -$2,000 in FY2022.

Analysis

Emmaus Life Sciences (EMMA) Gains from Sales and Divestitures (2021) Analysis & Trends

  • Per Business Quant data, EMMA's Gains from Sales and Divestitures was -$2,000 in FY2022 and $1,000 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 Emmaus Life Sciences 4.21 Mn -2.09 Mn 5.97 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 1,000.00
API Access

Emmaus Life Sciences Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=EMMA&period=max&api_key=YOUR_API_KEY